<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/FC59975E-26E8-4A62-ABD8-A570DC6ABF06"><gtr:id>FC59975E-26E8-4A62-ABD8-A570DC6ABF06</gtr:id><gtr:name>Keele University</gtr:name><gtr:department>Inst for Science and Tech in Medicine</gtr:department><gtr:address><gtr:line1>Keele</gtr:line1><gtr:line4>Newcastle</gtr:line4><gtr:line5>Staffordshire</gtr:line5><gtr:postCode>ST5 5BG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC59975E-26E8-4A62-ABD8-A570DC6ABF06"><gtr:id>FC59975E-26E8-4A62-ABD8-A570DC6ABF06</gtr:id><gtr:name>Keele University</gtr:name><gtr:address><gtr:line1>Keele</gtr:line1><gtr:line4>Newcastle</gtr:line4><gtr:line5>Staffordshire</gtr:line5><gtr:postCode>ST5 5BG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/78184215-8A64-4386-A8B1-8FDDDB0349ED"><gtr:id>78184215-8A64-4386-A8B1-8FDDDB0349ED</gtr:id><gtr:firstName>Divya</gtr:firstName><gtr:otherNames>Maitreyi</gtr:otherNames><gtr:surname>Chari</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FF013884%2F1"><gtr:id>5CE392B9-DA4D-42C7-96EF-9A0367880A24</gtr:id><gtr:title>Development of magnetic nanoparticle (MNP) based delivery system for gene transfer to multipotent neural precursor cells (NPCs)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/F013884/1</gtr:grantReference><gtr:abstractText>The adult brain and spinal cord (together called the central nervous system or CNS) have a poor capacity to repair after injury. This leads to a poor prognosis for patients with severe spinal cord injuries and devastating consequences for their quality of life. Neural precursor cells or NPCs, have an enormous potential for increasing repair at injury sites in the CNS. As NPCs have the ability to migrate into areas of damage in the nervous system, an important application for these cells is as cellular vehicles to transport therapeutic genes (and other molecules) to the sites of injury in the CNS. Currently, the most widely used method of delivering genes to NPCs is to use modified viruses carrying genes, which infect cells and then transfer genes into the infected cells. However, this method has a number of drawbacks and is associated with major safety issues. New delivery systems using magnetic nanoparticles (MNPs) could be very useful in this regard, and have many benefits for delivery of genes. MNPs can be coated with genes and are taken up into cells. As they are magnetic,cells carrying MNPs can be targeted to particular areas of damage in the body by placing external magnetic fields over injury sites.Preliminary clinical trials shown that injecting MNPs into the body appears to be safe and do not seem to have toxic or carcinogenic effects. This study will establish if it is possible to use MNPs to deliver therapeutic genes to NPCs (that will then be used for transplantation into the spinal cord). We will assess methods to optimise the uptake of MNPs coated with genes into NPCs and establish if this procedure has any adverse effects on the survival and development of the cells.</gtr:abstractText><gtr:technicalSummary>Several studies demonstrate that multipotent neural precursor cells (NPCs) have key properties for delivery of therapeutic genes to the damaged CNS. NPCs can migrate long distances in the CNS especially to sites of nervous system pathology (a phenomenon termed 'pathotropism'). This makes them valuable 'cellular vehicles' for gene delivery to areas of neural trauma. Most studies use conventional, virus based delivery systems for gene transfer to NPCs. Although efficient, these have a number of drawbacks including safety issues and production limitations. This highlights a major need for the development of alternative, nonviral approaches for gene transfer to neural cells, for both basic research and therapeutic applications. Novel delivery systems employing MNPs could have important benefits in this context including (i) Safety as evidenced by a range of Phase I/II clinical trials (2) Flexibility as MNPs can be 'functionalised' with DNA, siRNA or anti-sense oligonucleotides (3) Long term trackability in vivo using MRI and fluorescence imaging (4) Targetability of MNP labelled cells to focal sites of pathology (including the spinal cord) using external magnetic field gradients over target sites. Our pilot studies show avid MNP uptake by NPCs with limited toxic effects. Furthermore, MNPs could be used reproducibly to deliver a reporter gene to NPCs. Taken together, these findings highlight a potentially major application of MNPs for gene transfer to NPCs.This study will use well characterised models to address a range of key issues that will be critical to MNP mediated gene transfer to NPCs (derived for transplanation). These include an evaluation of the safety of MNPs for NPC labelling, the ability of MNPs to deliver a therapeutic gene to NPCs and the ability of transfected NPCs to deliver a therapeutic protein to the spinal cord. Additionally, we will test if a novel, oscillating magnetic array system can be used to enhance MNP transfection efficacy.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2008-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>355052</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multifunctional nanoparticles</gtr:description><gtr:id>EDA7CEC3-81E6-4491-8E48-438057B716B5</gtr:id><gtr:impact>Publication</gtr:impact><gtr:outcomeId>5460b97b0ff3d7.12681667-1</gtr:outcomeId><gtr:partnerContribution>Synthesised novel multifunctional particles</gtr:partnerContribution><gtr:piContribution>tested novel multifunctional nanoparticles for gene delivery and imaging in neural stem cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Pilot Award</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>National Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>BFBBBDD0-29E7-4B21-85BD-A9C70845FFE6</gtr:id><gtr:outcomeId>5460bc88895773.08760094</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Industry Doctoral Training Centre (IDTC)</gtr:department><gtr:description>PhD studentships</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>F793BA9B-2E53-411D-AD4A-D23ACB3B393A</gtr:id><gtr:outcomeId>5460be43c93242.26646760</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Landscape Fellowship</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>399CF294-49EB-4F0B-9F8E-6883D25D9502</gtr:id><gtr:outcomeId>5460bbc0b8e104.56178659</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>A55F13BF-5FFF-4003-AFAA-E876533B434C</gtr:id><gtr:outcomeId>5460bd17b5fe00.92634692</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Through this work, we were able to prove for the first time that major stem cell transplant populations, used for the repair of neurological injury and disease, can be safely genetically engineered using small magnetic nanoparticles, and that the process can be dramatically improved using applied oscillating magnetic fields. Such nanoparticles are emerging as a major class of medical materials, so we consider the proof we have provided can provide a clinically relevant way to engineer stem cells to improve their repair capacity.</gtr:description><gtr:exploitationPathways>The findings are of high relevance to the tissue engineering and neural transplantation fields as a clinically applicable method to genetically engineer stem cells. In addition, we are the first to prove that magnetic assistive devices, can increase gene delivery by nanoparticles, highlighting the need for further deveopoment of such assistive devices.</gtr:exploitationPathways><gtr:id>63891D02-5B2E-40D9-8A9D-CB8F93A1EFDB</gtr:id><gtr:outcomeId>56de96fce02696.67977860</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.keele.ac.uk/istm/staff/divyachari/</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>ADA6261A-6414-48E7-94A7-D5320AC2898E</gtr:id><gtr:title>The transfection of multipotent neural precursor/stem cell transplant populations with magnetic nanoparticles.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59460f82b4f3c554f1f2872bf40d05e5"><gtr:id>59460f82b4f3c554f1f2872bf40d05e5</gtr:id><gtr:otherNames>Pickard MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>5460b88e0058b5.07083359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B6FB171-583F-4071-854C-87AA5B713390</gtr:id><gtr:title>Using magnetic nanoparticles for gene transfer to neural stem cells: stem cell propagation method influences outcomes.</gtr:title><gtr:parentPublicationTitle>Journal of functional biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59460f82b4f3c554f1f2872bf40d05e5"><gtr:id>59460f82b4f3c554f1f2872bf40d05e5</gtr:id><gtr:otherNames>Pickard MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2079-4983</gtr:issn><gtr:outcomeId>585d410ccb88e5.07945347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37A736BA-55D1-46B4-AEC0-07D02E686743</gtr:id><gtr:title>Magnetic Nanoparticle-Mediated Gene Delivery to Two- and Three-Dimensional Neural Stem Cell Cultures: Magnet-Assisted Transfection and Multifection Approaches to Enhance Outcomes.</gtr:title><gtr:parentPublicationTitle>Current protocols in stem cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59460f82b4f3c554f1f2872bf40d05e5"><gtr:id>59460f82b4f3c554f1f2872bf40d05e5</gtr:id><gtr:otherNames>Pickard MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1938-8969</gtr:issn><gtr:outcomeId>58b7f4ab994364.44885490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A63F3E49-48F5-4AB8-9764-BD0BAF72233B</gtr:id><gtr:title>Fe3O4-PEI-RITC magnetic nanoparticles with imaging and gene transfer capability: development of a tool for neural cell transplantation therapies.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ca8c3fbce1152a76269b64e55145c4c"><gtr:id>3ca8c3fbce1152a76269b64e55145c4c</gtr:id><gtr:otherNames>Yiu HH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0724-8741</gtr:issn><gtr:outcomeId>5460b88dadcd72.65185943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4F295FE-CE3A-49A8-AB6A-8F065D9672FE</gtr:id><gtr:title>Robust uptake of magnetic nanoparticles (MNPs) by central nervous system (CNS) microglia: implications for particle uptake in mixed neural cell populations.</gtr:title><gtr:parentPublicationTitle>International journal of molecular sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59460f82b4f3c554f1f2872bf40d05e5"><gtr:id>59460f82b4f3c554f1f2872bf40d05e5</gtr:id><gtr:otherNames>Pickard MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1422-0067</gtr:issn><gtr:outcomeId>5460b88e49ced7.92620864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57C4105F-B27F-440F-9024-9490FC56CE54</gtr:id><gtr:title>'Stealth' nanoparticles evade neural immune cells but also evade major brain cell populations: Implications for PEG-based neurotherapeutics.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bbdfe56c42d174f5073215400f8d7f7"><gtr:id>0bbdfe56c42d174f5073215400f8d7f7</gtr:id><gtr:otherNames>Jenkins SI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>58b7f4ac54b452.74588168</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E3B1842-9522-45E7-B230-E683E7639CB7</gtr:id><gtr:title>Magnetic nanoparticle labeling of astrocytes derived for neural transplantation.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part C, Methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59460f82b4f3c554f1f2872bf40d05e5"><gtr:id>59460f82b4f3c554f1f2872bf40d05e5</gtr:id><gtr:otherNames>Pickard MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1937-3384</gtr:issn><gtr:outcomeId>5460b88e25d789.87734755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85DE7810-1E3D-4951-90A0-3C8B5030566D</gtr:id><gtr:title>Magnetic nanoparticle-mediated gene transfer to oligodendrocyte precursor cell transplant populations is enhanced by magnetofection strategies.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bbdfe56c42d174f5073215400f8d7f7"><gtr:id>0bbdfe56c42d174f5073215400f8d7f7</gtr:id><gtr:otherNames>Jenkins SI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn><gtr:outcomeId>5460b88dd23053.29534843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>249922B8-DADE-46CC-A4D7-2934E967CEC1</gtr:id><gtr:title>Uptake of systemically administered magnetic nanoparticles (MNPs) in areas of experimental spinal cord injury (SCI).</gtr:title><gtr:parentPublicationTitle>Journal of tissue engineering and regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f92dd1b9e7748a5eec5b11a307f430b"><gtr:id>5f92dd1b9e7748a5eec5b11a307f430b</gtr:id><gtr:otherNames>Jeffery ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6254</gtr:issn><gtr:outcomeId>5460b88e741670.24580729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1337396A-E490-49CB-ABE0-D39F465BA26C</gtr:id><gtr:title>Part II: Functional delivery of a neurotherapeutic gene to neural stem cells using minicircle DNA and nanoparticles: Translational advantages for regenerative neurology.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ad08e473c4cb5046087b70bd417d475"><gtr:id>7ad08e473c4cb5046087b70bd417d475</gtr:id><gtr:otherNames>Fernandes AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>58b7f4abce67a9.42734805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D103BA1D-E75C-4BD2-8041-CDF7F5D7C221</gtr:id><gtr:title>Part I: Minicircle vector technology limits DNA size restrictions on ex vivo gene delivery using nanoparticle vectors: Overcoming a translational barrier in neural stem cell therapy.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ad08e473c4cb5046087b70bd417d475"><gtr:id>7ad08e473c4cb5046087b70bd417d475</gtr:id><gtr:otherNames>Fernandes AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>58b7f4ac250240.58000254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CADA2BA-8E59-4DDD-A875-F86253B1C704</gtr:id><gtr:title>Differences in magnetic particle uptake by CNS neuroglial subclasses: implications for neural tissue engineering.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bbdfe56c42d174f5073215400f8d7f7"><gtr:id>0bbdfe56c42d174f5073215400f8d7f7</gtr:id><gtr:otherNames>Jenkins SI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>5460b88d8a6477.17132776</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/F013884/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>